Praxis Precision Medicines (PRAX) Accounts Payables (2019 - 2026)

Praxis Precision Medicines' Accounts Payables history runs 8 years deep, the most recent figure standing at $31.2 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 36.01% year-over-year to $31.2 million in Q1 2026; TTM through Mar 2026 was $31.2 million, a 36.01% increase from a year earlier, with the FY2025 full-year figure at $24.6 million, up 96.58% from the prior year.
• Accounts Payables climbed to $31.2 million in Q1 2026 per PRAX's latest filing, from $24.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $31.2 million in Q1 2026 and bottomed at $5.8 million in Q4 2023.
• The 5-year median for Accounts Payables is $13.3 million (2022), against an average of $16.0 million.
• Across the five-year window, Accounts Payables plunged 60.37% in 2023 and jumped 251.82% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $14.7 million in 2022, then plunged by 60.37% to $5.8 million in 2023, then soared by 115.44% to $12.5 million in 2024, then surged by 96.58% to $24.6 million in 2025, then increased by 26.51% to $31.2 million in 2026.
• Per Business Quant, the three latest PRAX Accounts Payables figures stand at $31.2 million (Q1 2026), $24.6 million (Q4 2025), and $30.8 million (Q3 2025).